Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

RMAT Designation, Gene Therapies Highlight 2017 CBER Transformation

Jan 18 2018

• By Michael Cipriano

Related Content

Regenerative Medicine Clinical Trials: US FDA Supports Studies Comparing Multiple Agents

Nov 17 2017

Spark's Early Christmas Present: US FDA Approves Luxturna For Vision Loss

Dec 19 2017

How To Build An Endpoint: Spark Designed Testing Maze To Study Rare Vision Loss

Oct 15 2017

Kite's Gene Therapy Yescarta Gets Biosimilar Treatment With Second-In-Class Approval

Oct 20 2017

US FDA First's RMAT Designation: Humacyte Got A 'Quick Response'

Mar 26 2017

Related Companies

Humacyte, Inc.

Novartis AG

Kite Pharma, Inc.

Spark Therapeutics, Inc.

Dynavax Technologies Corporation

Additional Topics

United States Biologics Drug Review Review Pathway FDA Regulation BioPharmaceutical

More from Product Reviews

More from Pink Sheet

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window